Zhaoyan Pharmaceutical (06127) rose more than 6%. As of press release, it rose 6.65% to HK$80.50, with a turnover of HK$5.129 million.
The Zhitong Finance App learned that Zhaoyan New Pharmaceutical (06127) rose by more than 6%. As of press release, it had risen 6.65% to HK$80.50, with a turnover of HK$5.129 million.
According to the news, Zhaoyan Pharmaceutical announced that it is expected to achieve operating revenue of about 0.719 billion yuan to 0.973 billion yuan (RMB, same below) from January to June 2024. Compared with the data for the same period last year, it will decrease by about 38.6417 million yuan to 0.293 billion yuan, a year-on-year decrease of about 3.8% to 28.9%. Net profit attributable to shareholders of listed companies is expected to be about -0.184 billion yuan to -0.136 billion yuan from January to June 2024. Compared with the data for the same period last year, there will be a loss.
According to the announcement, during the reporting period, due to the popularity of investment and financing in the pharmaceutical industry and changes in market demand, the company's operating income declined, sales order profit margins were compressed due to increased competition in the same industry, the company's gross margin decreased year-on-year, and the net profit of the company's laboratory service business declined markedly year-on-year, and small losses may occur.